On May 13, 2026, VCbeat officially released the list of the 10 most commercially promising non-invasive brain-computer interface products for 2026. Hangzhou NEUREAL Technology Co., Ltd. was successfully selected due to its innovative product system deeply integrating BCI+VR and AI, along with a mature commercialization path, becoming a benchmark enterprise in China's non-invasive BCI medical sector.
This list was published by VCbeat Think Tank, based on a tripartite evaluation system of "technological breakthrough—clinical progress—commercial potential," conducting multi-dimensional quantitative scoring for nearly 50 non-invasive brain-computer interface products, where technological innovation and clinical application each account for
30% weight, while commercial potential accounts for 40% weight, comprehensively selecting industry benchmark products and enterprises with scalable implementation capabilities.
Driven by both technology and clinical practice, demonstrating core commercial competitiveness
As a National Specialized, Refined, Differential, and Innovative (SRDI) "Little Giant" enterprise, NEUREAL has long been deeply engaged in the fields of non-invasive brain-computer interfaces and digital healthcare. With BCI+X as its core technical foundation, it has built a full-chain closed-loop solution covering "screening—assessment—intervention—rehabilitation." This selection fully validates NEUREAL's comprehensive strength in technological innovation, clinical translation, and market expansion.
NEUREAL's current core product, the BCI+X Precision Diagnosis and Treatment Platform for Brain Disorders, utilizes multimodal precise induction and dynamic target spatiotemporal localization and intervention technologies to collect neural signals with higher signal-to-noise ratio and stability. It also relies on a general "stimulation-brain state" mapping model combined with dynamic regulation synergy technologies to achieve precise assessment and a closed-loop dynamic intervention, establishing unique core technical barriers.
In terms of clinical and commercial achievements, NEUREAL has currently obtained over 80 patents and software copyrights, along with a total of 7 medical device registration certificates, including international certifications such as EU CE and UK MHRA. It has been awarded the title of National SRDI "Little Giant" enterprise. Currently, NEUREAL's products have been deployed in over 1,000 hospitals domestically and more than ten hospitals overseas, serving nearly 10 million person-times, further enhancing industry and market recognition.
Empowering brain health through technological innovation, leading high-quality industrial development
The year 2026 serves as a critical window for the scaled application of the brain-computer industry. Boosted by policy, capital, and supply chain collaboration, China's brain-computer interface industry is steadily crossing the tipping point of technological breakthroughs and moving towards a new stage of explosive scaled implementation.
This selection is not only high recognition of the company's strength by the industry but also the starting point of a new journey. NEUREAL will continue to deepen its engagement in the deep integration of brain-computer interfaces with VR and AI technologies, increase R&D investment in areas such as multimodal neural data platforms and BCI hardware, collaborate with top-tier hospitals and research institutions, and promote the implementation of more innovative results.
In the future, NEUREAL will remain committed to its mission of benefiting one billion patients with brain disorders. With non-invasive brain-computer interface technology at its core, we are building a full-cycle brain health ecosystem covering prevention, screening, treatment, and rehabilitation, using technology to safeguard brain health and support the implementation of the Healthy China strategy.
